Amphastar Pharmaceuticals Zukünftiges Wachstum
Future Kriterienprüfungen 3/6
Amphastar Pharmaceuticals wird ein jährliches Gewinn- und Umsatzwachstum von 13.6% bzw. 9.7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 13.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 24.8% betragen.
Wichtige Informationen
13.6%
Wachstumsrate der Gewinne
13.2%
EPS-Wachstumsrate
| Pharmaceuticals Gewinnwachstum | 23.8% |
| Wachstumsrate der Einnahmen | 9.7% |
| Zukünftige Eigenkapitalrendite | 24.8% |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 12 Nov 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Amphastar: Objectively Undervalued But For Good Reason (Rating Downgrade)
Oct 25Investors Continue Waiting On Sidelines For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)
Sep 15
Amphastar: Perplexing Pipeline, Lumpy Revenues - I'm On Sidelines
Sep 12Is Amphastar Pharmaceuticals (NASDAQ:AMPH) Using Too Much Debt?
Aug 27Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?
Jul 05Amphastar Pharmaceuticals: Shining Star Soon To Fade With Competitive Pressures Looming
Jul 01Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Subdued P/E Might Signal An Opportunity
May 30Amphastar Pharmaceuticals: Buy When Fear Is Overblown
May 30Reassessing Amphastar Pharmaceuticals
May 15Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet
Mar 27Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions
Mar 04Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today
Jan 04Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E
Dec 20Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet
Dec 03Amphastar Pharmaceuticals (NASDAQ:AMPH) Ticks All The Boxes When It Comes To Earnings Growth
Sep 18An Intrinsic Calculation For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Suggests It's 35% Undervalued
Sep 03These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely
Aug 17Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Well Worth Watching
Jun 02We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease
May 11Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Intrinsic Value Is Potentially 51% Above Its Share Price
Mar 02Is Now The Time To Put Amphastar Pharmaceuticals (NASDAQ:AMPH) On Your Watchlist?
Feb 07Does Amphastar Pharmaceuticals (NASDAQ:AMPH) Have A Healthy Balance Sheet?
Jan 24Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors
Nov 02Amphastar: A Pharmaceutical Growth Stock
Oct 06Amphastar wins FDA approval for Epinephrine pre-filled syringes
Aug 16Amphastar Pharmaceuticals: Compelling Growth Prospects For H2 2022 And Beyond
Aug 08Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?
Jul 24Amphastar generic vasopressin for increasing blood pressure gets FDA approval
Jul 19Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 882 | 222 | 222 | 286 | 4 |
| 12/31/2025 | 813 | 198 | 202 | 249 | 5 |
| 12/31/2024 | 738 | 180 | 169 | 222 | 5 |
| 9/30/2024 | 724 | 158 | 170 | 208 | N/A |
| 6/30/2024 | 713 | 167 | 178 | 213 | N/A |
| 3/31/2024 | 676 | 155 | 161 | 198 | N/A |
| 12/31/2023 | 644 | 138 | 145 | 184 | N/A |
| 9/30/2023 | 601 | 135 | 140 | 175 | N/A |
| 6/30/2023 | 541 | 102 | 100 | 131 | N/A |
| 3/31/2023 | 519 | 93 | 51 | 79 | N/A |
| 12/31/2022 | 499 | 91 | 65 | 89 | N/A |
| 9/30/2022 | 485 | 77 | 90 | 114 | N/A |
| 6/30/2022 | 477 | 91 | 70 | 97 | N/A |
| 3/31/2022 | 455 | 81 | 100 | 126 | N/A |
| 12/31/2021 | 438 | 62 | 71 | 98 | N/A |
| 9/30/2021 | 413 | 36 | 45 | 74 | N/A |
| 6/30/2021 | 384 | 10 | 52 | 81 | N/A |
| 3/31/2021 | 368 | 2 | 45 | 79 | N/A |
| 12/31/2020 | 350 | 1 | 23 | 57 | N/A |
| 9/30/2020 | 337 | 7 | 13 | 46 | N/A |
| 6/30/2020 | 334 | 4 | -11 | 25 | N/A |
| 3/31/2020 | 327 | 52 | 12 | 47 | N/A |
| 12/31/2019 | 322 | 49 | 0 | 42 | N/A |
| 9/30/2019 | 329 | 52 | 3 | 46 | N/A |
| 6/30/2019 | 324 | 53 | 27 | 73 | N/A |
| 3/31/2019 | 316 | 2 | -23 | 26 | N/A |
| 12/31/2018 | 295 | -6 | -4 | 38 | N/A |
| 9/30/2018 | 265 | -7 | -5 | 38 | N/A |
| 6/30/2018 | 248 | -9 | N/A | 25 | N/A |
| 3/31/2018 | 242 | -4 | N/A | 25 | N/A |
| 12/31/2017 | 240 | 4 | N/A | 39 | N/A |
| 9/30/2017 | 243 | 0 | N/A | 43 | N/A |
| 6/30/2017 | 250 | 4 | N/A | 42 | N/A |
| 3/31/2017 | 252 | 9 | N/A | 47 | N/A |
| 12/31/2016 | 255 | 10 | N/A | 39 | N/A |
| 9/30/2016 | 269 | 21 | N/A | 28 | N/A |
| 6/30/2016 | 268 | 14 | N/A | 30 | N/A |
| 3/31/2016 | 254 | 0 | N/A | 23 | N/A |
| 12/31/2015 | 252 | -3 | N/A | 11 | N/A |
| 9/30/2015 | 230 | -13 | N/A | 20 | N/A |
| 6/30/2015 | 226 | -15 | N/A | 30 | N/A |
| 3/31/2015 | 221 | -10 | N/A | 28 | N/A |
| 12/31/2014 | 210 | -11 | N/A | 21 | N/A |
| 9/30/2014 | 209 | -6 | N/A | 17 | N/A |
| 6/30/2014 | 209 | -1 | N/A | 4 | N/A |
| 3/31/2014 | 223 | 8 | N/A | 24 | N/A |
| 12/31/2013 | 230 | 12 | N/A | 31 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: AMPHDas prognostizierte Gewinnwachstum (13.6% pro Jahr) liegt über der Sparquote (2.6%).
Ertrag vs. Markt: AMPHDie Erträge des Unternehmens (13.6% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (15.4% pro Jahr).
Hohe Wachstumserträge: AMPHDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: AMPHDie Einnahmen des Unternehmens (9.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (9% pro Jahr).
Hohe Wachstumseinnahmen: AMPHDie Einnahmen des Unternehmens (9.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: AMPHDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (24.8%)